Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer

pharmafileNovember 19, 2018

Tag: AstraZeneca , NSCLC , metastatic

PharmaSources Customer Service